Business Update & Financial Outlook

Strong underlying Q2 performance1 Q2 Worldwide Sales Full Year Sales $59.3B +22% GUIDANCE RANGE $58.6B-$59.6B $15.0B +3% +14% ex-Exchange, ex-LAGEVRIO² Q2 Non-GAAP LPS3 $48.7B +17% 2021 Full Year Non-GAAP EPS5 2022 2023 ($2.06) N/M² Includes one-time charge of $4.02 from Prometheus acquisition $5.37 2021 $7.48 2022 GUIDANCE RANGE $2.95 - $3.05 1. Results from continuing operations attributable to Merck & Co., Inc. 2. Excludes Lagevrio sales of $203 million in 2Q23 and $1.2 billion in 2022. 3. GAAP LPS (Loss Per Share) of ($2.35). Both 2Q23 GAAP and non-GAAP LPS reflect a charge of $10.2 billion or $4.02 per share for the acquisition of Prometheus Biosciences, Inc. 4. Not meaningful 5. Merck does not exclude expenses for upfront and milestone payments related to collaborations and licensing agreements, or charges related to pre-approval assets obtained in transactions accounted for as asset acquisitions from its non-GAAP results. YTD 2023 non-GAAP results include an aggregate $11.6 billion or $4.53 per share of R&D expenses related to the Prometheus and Imago acquisitions and upfront payment for the license and collaboration agreement with Kelun. Full year 2022 non-GAAP results include $690 million or $0.22 of such charges. Full year 2021 non-GAAP results include $1.7 billion or $0.65 of such charges. For 2023, outlook does not assume any additional significant potential business development transactions. 2023 MERCK 6

View entire presentation